MedFirst Healthcare Services, Inc. (TW) AI Stock Analysis
MedFirst Healthcare Services, Inc. (TW) (4175) AI Stock Analysis
MedFirst Healthcare Services, Inc. (TW)
(TPEx:4175)
MedFirst Healthcare Services earns a moderate score. Financial fundamentals carry the most weight and are improving: record revenue near NT$8.0 billion, the strongest gross margin in six years, earnings more than doubling, and robust free cash flow of NT$624 million that exceeds reported profit. These strengths are tempered by a leveraged balance sheet with debt at 2.3 times equity and net margins below 2%, leaving limited buffer against cost or pricing shocks. An undemanding 12.9 P/E and a 6.12% dividend yield add meaningful support to the score. The main drag is technical: the share price sits below all key moving averages with negative MACD momentum, though oversold RSI and Stochastic readings suggest selling pressure may be nearing exhaustion. Overall, a cash-generative, cheaply valued income candidate whose leverage and weak price trend warrant caution.
MedFirst Healthcare Services, Inc. (TW) (4175) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.09B
- Dividend Yield
- 6.08%
- Average Volume (3M)
- 11.11K
- Price to Earnings (P/E)
- 13.0
- Beta (1Y)
- 0.21
- Revenue Growth
- 2.49%
- EPS Growth
- 5.18%
- Country
- TW
- Employees
- 150
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
MedFirst Healthcare Services, Inc. (TW) Business Overview & Revenue Model
Company Description
MedFirst Healthcare Services, Inc., established in 1990 and headquartered in Taoyuan City, Taiwan, is a prominent distributor of medical supplies throughout Taiwan and China. The company's diverse product range includes diabetes management items, res...
MedFirst Healthcare Services, Inc. (TW) Financial Statement Overview
Summary
A mixed but improving profile. Cash flow is the standout (score 73): operating cash flow rebounded to NT$904 million and free cash flow to NT$624 million, far exceeding net income and comfortably covering interest, capex and gradual debt reduction. The income statement (score 61) shows six consecutive years of revenue growth to roughly NT$8.0 billion, the best gross margin in six years at 32.5%, and net income more than doubling to NT$156 million — though growth has slowed to low-to-mid single digits and net margin remains razor-thin at about 1.9% with a history of volatility. The balance sheet is the weak link (score 49), with debt of NT$3.59 billion against equity of only NT$1.56 billion (2.3x debt-to-equity) and equity funding just over one-fifth of assets, partially offset by four straight years of deleveraging and ROE improving to about 10%.
Income Statement
61PositiveBalance Sheet
49NeutralCash Flow
73Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.06B | 8.01B | 7.73B | 7.45B | 7.22B | 6.54B |
| Gross Profit | 2.65B | 2.60B | 2.38B | 2.27B | 2.21B | 1.93B |
| EBITDA | 794.07M | 991.07M | 924.25M | 873.32M | 940.99M | 686.17M |
| Net Income | 160.34M | 155.57M | 69.81M | 46.80M | 170.86M | 67.93M |
Balance Sheet | ||||||
| Total Assets | 7.31B | 7.28B | 7.12B | 7.63B | 7.55B | 6.81B |
| Cash, Cash Equivalents and Short-Term Investments | 570.70M | 533.99M | 624.58M | 961.38M | 1.01B | 841.36M |
| Total Debt | 3.52B | 3.59B | 3.64B | 3.88B | 3.94B | 3.61B |
| Total Liabilities | 5.78B | 5.72B | 5.66B | 6.18B | 6.19B | 5.63B |
| Stockholders Equity | 1.52B | 1.56B | 1.46B | 1.45B | 1.36B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | 850.53M | 624.41M | 404.82M | 572.08M | 805.35M | 587.94M |
| Operating Cash Flow | 982.35M | 903.97M | 542.24M | 795.40M | 1.07B | 1.00B |
| Investing Cash Flow | -167.87M | -307.49M | -207.97M | -253.30M | -221.49M | -397.75M |
| Financing Cash Flow | -818.76M | -715.11M | -754.72M | -603.48M | -611.30M | -188.06M |
MedFirst Healthcare Services, Inc. (TW) Peers Comparison
Overall Rating
TW:413868Neutral
TW:415564Neutral
TW:417560Neutral
TW:474753Neutral
TW:410847Neutral
TW:679640Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | TWD 2.15B | 15.50 | ― | 7.81% | -1.10% | -16.90% | |
| 64Neutral | TWD 2.19B | 10.29 | ― | 1.71% | -10.90% | ― | |
| 60Neutral | TWD 2.09B | 12.99 | ― | 6.08% | 2.49% | 5.18% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | TWD 1.60B | -25.78 | ― | 2.99% | 4.56% | -172.55% | |
| 47Neutral | TWD 2.06B | -48.21 | ― | ― | 3.62% | 34.40% | |
| 40Underperform | TWD 2.04B | 127.00 | ― | 0.49% | 12.26% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4175 | MedFirst Healthcare Services, Inc. (TW) | 49.35 | -5.02 | -9.23% | |
| TW:4108 | Phytohealth Corporation | 10.35 | -3.90 | -27.37% | |
| TW:4138 | Dynamic Medical Technologies Inc. | 53.80 | -5.91 | -9.90% | |
| TW:4155 | Ok Biotech Co., Ltd. | 17.50 | 2.12 | 13.81% | |
| TW:4747 | Johnson Chemical Pharmaceutical Works Co., Ltd. | 17.55 | -14.17 | -44.68% | |
| TW:6796 | Medimaging Integrated Solution Inc. | 50.80 | -38.62 | -43.19% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
